期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 17, 期 12, 页码 1464-1472出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2019.0059
关键词
-
类别
资金
- AstraZeneca
- Celgene Corporation
- Clovis Oncology
- Eisai
- Genentech
- Genomic Health, Inc.
- Novartis
- Taiho Oncology, Inc.
- TESARO
- AbbVie
- Amgen
- Gilead Sciences, Medical Affairs
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as preferred interventions, whereas others are categorized as either other recommended interventions or useful under certain circumstances.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据